Published in Arthritis Rheum on August 01, 2008
Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci U S A (2010) 2.43
The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol (2015) 1.89
Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol (2011) 1.81
Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A (2008) 1.69
Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol (2014) 1.66
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther (2011) 1.61
Th17 cytokines and arthritis. Semin Immunopathol (2010) 1.57
From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol Rev (2010) 1.52
Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis. PLoS Genet (2009) 1.36
High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol (2010) 1.33
Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint. PLoS One (2010) 1.31
Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology (2014) 1.25
Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond. Nat Rev Rheumatol (2010) 1.23
Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol (2014) 1.17
Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol (2009) 1.16
The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One (2009) 1.16
Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol (2010) 1.15
Expression of Th-17 and RORγt mRNA in Behçet's Disease. Med Sci Monit (2011) 1.13
Evaluating cellular polyfunctionality with a novel polyfunctionality index. PLoS One (2012) 1.11
IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A (2012) 1.09
The role of T helper type 17 cells in inflammatory arthritis. Clin Exp Immunol (2009) 1.03
Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther (2013) 1.03
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroenterol (2009) 0.98
Current perspectives on the role of IL-17 in autoimmune disease. J Inflamm Res (2010) 0.96
Disease modification in ankylosing spondylitis. Nat Rev Rheumatol (2010) 0.96
Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Res Ther (2011) 0.96
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A (2015) 0.95
Progress in spondylarthritis. Progress in studies of the genetics of ankylosing spondylitis. Arthritis Res Ther (2009) 0.94
Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis. Clin Exp Immunol (2013) 0.93
Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome-wide expression profiling and real-time polymerase chain reaction. Arthritis Rheum (2009) 0.93
Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease? Arthritis Res Ther (2009) 0.93
The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis. Int J Rheumatol (2012) 0.92
Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol (2012) 0.92
Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int (2011) 0.92
Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis (2013) 0.89
Enhanced and persistent levels of interleukin (IL)-17⁺ CD4⁺ T cells and serum IL-17 in patients with early inflammatory arthritis. Clin Exp Immunol (2013) 0.88
CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets (2010) 0.88
Adaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy. Clin Dev Immunol (2011) 0.87
The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma. Inflammation (2015) 0.87
Ankylosing spondylitis: from cells to genes. Int J Inflam (2013) 0.86
Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells. Cytokine (2015) 0.85
New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis. Arthritis Res Ther (2012) 0.85
Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings. Rheumatol Int (2010) 0.84
Salmonella enterica induces joint inflammation and expression of interleukin-17 in draining lymph nodes early after onset of enterocolitis in mice. Infect Immun (2012) 0.84
T-helper 17 lymphocytes in ocular cicatricial pemphigoid. Mol Vis (2009) 0.84
B cells contribute to heterogeneity of IL-17 producing cells in rheumatoid arthritis and healthy controls. PLoS One (2013) 0.83
The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights (2014) 0.83
Early axial spondyloarthritis. Curr Opin Rheumatol (2010) 0.82
IL-23 and IL-17 in ankylosing spondylitis. Rheumatol Int (2009) 0.81
Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Invest Dermatol (2014) 0.80
Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol (2015) 0.80
Role of IL-38 and its related cytokines in inflammation. Mediators Inflamm (2015) 0.79
Production of Proinflammatory Cytokines by Monocytes in Liver-Transplanted Recipients with De Novo Autoimmune Hepatitis Is Enhanced and Induces TH1-like Regulatory T Cells. J Immunol (2016) 0.79
Relationship of CD146 expression to secretion of interleukin (IL)-17, IL-22 and interferon-γ by CD4(+) T cells in patients with inflammatory arthritis. Clin Exp Immunol (2015) 0.78
Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol (2015) 0.78
How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis. Clin Dev Immunol (2013) 0.78
Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. J Transl Med (2015) 0.78
Activation-Induced Killer Cell Immunoglobulin-like Receptor 3DL2 Binding to HLA-B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis. Arthritis Rheumatol (2016) 0.77
HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats. PLoS One (2015) 0.77
Biologic agents in juvenile spondyloarthropathies. Pediatr Rheumatol Online J (2016) 0.77
Old and new treatment targets in axial spondyloarthritis. RMD Open (2015) 0.77
[Th17 cells - a new proinflammatory T cell population and its role in rheumatologic autoimmune diseases]. Z Rheumatol (2009) 0.76
The role of IL-17 in vitiligo: A review. Autoimmun Rev (2016) 0.76
Mediators of inflammation and bone remodeling in rheumatic disease. Semin Cell Dev Biol (2015) 0.76
Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatol Ther (2016) 0.76
The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients. PLoS One (2013) 0.76
Overexpression and unique rearrangement of VH2 transcripts in immunoglobulin variable heavy chain genes in ankylosing spondylitis patients. Exp Mol Med (2010) 0.76
Increase risk of allergic diseases in patients with ankylosing spondylitis: A 10-year follow-up population-based study in Taiwan. Medicine (Baltimore) (2016) 0.75
Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulating Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis. J Transl Med (2016) 0.75
Autoinflammation and HLA-B27: Beyond Antigen Presentation. Ocul Immunol Inflamm (2016) 0.75
Adalimumab monotherapy in a patient with psoriatic arthritis associated with chronic renal failure on hemodialysis: a case report and literature review. Clin Med Insights Case Rep (2012) 0.75
Functional improvement of regulatory T cells from rheumatoid arthritis subjects induced by capsular polysaccharide glucuronoxylomannogalactan. PLoS One (2014) 0.75
Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials. Drug Des Devel Ther (2016) 0.75
Functional defects in CD4(+) CD25(high) FoxP3(+) regulatory cells in ankylosing spondylitis. Sci Rep (2016) 0.75
Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag (2016) 0.75
A Single Nucleotide Polymorphism in the Il17ra Promoter Is Associated with Functional Severity of Ankylosing Spondylitis. PLoS One (2016) 0.75
Immune cell transcript modules reveal leukocyte heterogeneity in synovial biopsies of seronegative spondylarthropathy patients. BMC Musculoskelet Disord (2014) 0.75
Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther (2017) 0.75
Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders. Exp Ther Med (2016) 0.75
Secukinumab: a promising therapeutic option in spondyloarthritis. Clin Rheumatol (2016) 0.75
Patient Burden of Axial Spondyloarthritis. J Clin Rheumatol (2017) 0.75
Reduced serum B7-H3 levels in patients with ankylosing spondylitis. Inflammation (2015) 0.75
The Pathway Tools software. Bioinformatics (2002) 14.89
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum (2007) 2.37
Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci U S A (2009) 2.27
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93
EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem (2006) 1.91
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum (2007) 1.85
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol (2009) 1.81
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
D²P²: database of disordered protein predictions. Nucleic Acids Res (2012) 1.75
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum (2013) 1.67
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Rational drug design via intrinsically disordered protein. Trends Biotechnol (2006) 1.57
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics (2014) 1.50
Transcriptional profiling of Caulobacter crescentus during growth on complex and minimal media. J Bacteriol (2004) 1.46
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene (2002) 1.42
Conservation of intrinsic disorder in protein domains and families: I. A database of conserved predicted disordered regions. J Proteome Res (2006) 1.42
Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med (2003) 1.41
IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol (2009) 1.39
Heat shock cognate protein 70 is involved in rotavirus cell entry. J Virol (2002) 1.37
Rotavirus gene silencing by small interfering RNAs. EMBO Rep (2002) 1.36
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol (2007) 1.32
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res (2012) 1.30
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol (2006) 1.28
Lack of BRAF mutations in uveal melanoma. Cancer Res (2003) 1.27
Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum Gene Ther (2002) 1.27
Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother (2004) 1.27
Conservation of intrinsic disorder in protein domains and families: II. functions of conserved disorder. J Proteome Res (2006) 1.27
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res (2011) 1.25
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res (2013) 1.25
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol (2009) 1.25
Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med (2002) 1.25
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25
Exploring the binding diversity of intrinsically disordered proteins involved in one-to-many binding. Protein Sci (2013) 1.23
Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep (2012) 1.19
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2003) 1.19
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol (2003) 1.17
Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J Immunol (2002) 1.17
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest (2014) 1.16
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 1.16
NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells. J Immunol (2012) 1.14
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res (2011) 1.14
Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. J Immunol Methods (2006) 1.13
Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. J Transl Med (2011) 1.13
A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol (2006) 1.13
Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol (2011) 1.13
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol (2008) 1.12
Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. Eur J Cardiothorac Surg (2006) 1.12
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res (2006) 1.11
Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol (2002) 1.11
In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol (2002) 1.10
Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol (2009) 1.09
CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol (2002) 1.09
Aldosterone-induced serum and glucocorticoid-induced kinase 1 expression is accompanied by Nedd4-2 phosphorylation and increased Na+ transport in cortical collecting duct cells. J Am Soc Nephrol (2005) 1.09
Interaction of rotaviruses with Hsc70 during cell entry is mediated by VP5. J Virol (2003) 1.08
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res (2004) 1.08
Low-back pain in children. Lancet (2003) 1.08
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol (2003) 1.07
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res (2004) 1.07
Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res (2014) 1.06